Lanreotide and Pegvisomant: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 9, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lanreotide
No brand names on recordPegvisomant
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Elevated liver enzymes
Interaction Deep Dive
In a postmarketing study, 3 out of 26 patients (approximately 10%) receiving octreotide acetate and pegvisomant combination therapy experienced elevated ALT and AST serum concentrations of 13 to 45 times the ULN within 3 months of treatment initiation. Supratherapeutic doses of octreotide acetate (30 mg every 2 weeks) were administered with a normal dose of pegvisomant (10 mg/day) to 2 of those patients. All three patients recovered following discontinuation of therapy. In another study, 11 out of 32 patients receiving pegvisomant and a somatostatin analogue (at normal doses) experienced elevated liver enzymes. Marked hepatic transaminase elevations greater than 10 times the ULN were reported in two of those patients, at least one of which was receiving octreotide acetate1.
Why it happens (mechanism)
Unknown
Common questions
Can I take Lanreotide and Pegvisomant together?
Elevated liver enzymes Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lanreotide and Pegvisomant interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Lanreotide or Pegvisomant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Health Canada: Health Canada Endorsed Important Safety Information on SOMAVERT(R) (pegvisomant). Health Canada. Ottawa, Canada. 2007.
Keep reading about Lanreotide
Keep reading about Pegvisomant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist